Physician profile
Robert W Chan
NPI 1508826488
$10,552.49
in general payments reported to CMS, 2019-2025
35 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,858 · 2020: $1,218 · 2021: $1,383 · 2022: $1,466 · 2023: $632 · 2024: $624 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,626.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,137.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,106.14 | 2019-2024 | Farxiga, Breztri |
| Amarin Pharma, INC. | $1,043.06 | 2019-2022 | |
| Abbvie INC. | $851.12 | 2019-2024 | Linzess, Viberzi, Creon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $802.06 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $799.03 | 2019-2025 | Ozempic, Rybelsus |
| Axonics, INC. | $756.95 | 2022-2024 | Axonics |
| Amgen INC. | $753.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $519.04 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Lilly USA, LLC | $382.80 | 2019-2025 | Mounjaro, Jardiance |
| Gilead Sciences, INC. | $328.76 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $328.01 | 2019-2024 | |
| Radius Health, INC. | $279.17 | 2019-2023 | Tymlos |
| Janssen Pharmaceuticals, INC | $243.36 | 2019-2021 | |
| Exact Sciences Corporation | $220.75 | 2023-2024 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $110.34 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $108.63 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $92.49 | 2019-2020 | |
| Abbott Laboratories | $84.35 | 2024-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $82.44 | 2019-2020 | |
| Allergan, INC. | $62.85 | 2019 | |
| Boston Scientific Corporation | $57.93 | 2021 | |
| Dexcom, INC. | $53.85 | 2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $48.39 | 2019 | |
| Glaxosmithkline, LLC. | $41.54 | 2020 | |
| Ibsa Pharma INC. | $39.29 | 2021 | |
| Mannkind Corporation | $37.15 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $30.70 | 2020-2021 | |
| Ambu INC. | $30.24 | 2021 | |
| Hologic Sales and Service, LLC | $24.39 | 2023 | Aptima |
| Cmp Pharma, INC. | $24.33 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.15 | 2023 | Xifaxan, Trulance |
| Blue Earth Diagnostics | $19.51 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.24 | 2019 | |
| Scilex Pharmaceuticals INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.